Publications associées à Towards new tuberculosis drugs

Innovative Tools and in vivo Methods for Tuberculosis Drug Discovery and Development

Worldwide, tuberculosis (TB) is the leading cause of death due to a single infectious agent, claiming 1.6 million human lives and causing >10 million new cases in 2017 alone, mostly in low-income regions. The intracellular pathogen Mycobacterium tuberculos ...

EPFL2019

More Medicines for Tuberculosis: Fuelling Drug Discovery against Mycobacterium tuberculosis

Shi-Yan Caroline Foo

Tuberculosis (TB), whose etiological agent is Mycobacterium tuberculosis (M. tuberculosis), has plagued humanity since antiquity. Even with chemotherapy available today, TB is the leading cause of death due to an infectious disease. Modern day factors, suc ...

EPFL2018

Method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof

Martinus Gijs, Déborah Heintze, Ata Tuna Ciftlik, Diego Gabriel Dupouy

The invention relates to a method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof. In particular, the invention relates to a method which is a useful tool for use in the field of diagnosis, prevention and/or treat ...

2017

2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides

2-homopiperazine-1-yl-4H-l, 3 -bensothiazine-4-one derivatives of formula (I) are provided. They are useful in the treatment of bacterial infections, in particular tuberculosis, buruli ulcer and leprosy. A process for the preparation of 2- (homo)piperazine ...

2016

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor

John McKinney, Neeraj Dhar, François Signorino-Gelo

Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage of ison ...

Elsevier Science Bv2016

Benzimidazole sulfide derivatives for the treatment or prevention of tuberculosis

Stewart Cole, Jan Lars Rybniker

The present invention relates to the use of benzimidazole sulfide derivatives and prodrugs thereof in the treatment and/or prevention of tuberculosis. ...

2016

Benzothiophene, benzyloxybenzylidene and indoline derivatives useful for the treatment of tuberculosis

Stewart Cole, Jan Lars Rybniker

The present invention relates to benzothiophene, benzyloxybenzylidene and indoline-2-one derivatives and the use of said derivatives in the treatment and/or prevention of tuberculosis. ...

2016

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

Stewart Cole

About 1.3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex r ...

Elsevier Science Inc2014

Detection and treatment of subclinical tuberculosis

Stewart Cole

Reduction of active disease by preventive therapy has the potential to make an important contribution towards the goal of tuberculosis (TB) elimination. This report summarises discussions amongst a Working Group convened to consider areas of research that ...

Elsevier2012

2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections

Stewart Cole

The present invention relates to new 2-piperazin-1-yl-4H-1,3-benzothiazin- 4-one derivatives and their use for the treatment of mammalian infections caused by bacteria, especially diseases like tuberculosis (TB), Buruli ulcer and leprosy that result from i ...

2012

Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers

Hubert van den Bergh, Patrycja Nowak-Sliwinska

Multidrug resistance (MDR) remains a primary hindrance to curative cancer therapy. Thus, introduction of novel strategies to overcome MDR is of paramount therapeutic significance. Sequestration of chemotherapeutics in lysosomes is an established mechanism ...

2012

Rising standards for tuberculosis drug development

Stewart Cole

Development of new drugs to treat tuberculosis (TB) faces even more constraints than the development of therapeutic agents for other diseases. This is due, in part, to intrinsic properties of the tubercle bacillus, such as its slow growth, phenotypic drug ...

2008

Photodynamic therapy for 101 early cancers of the upper aerodigestive tract, the esophagus, and the bronchi: a single-institution experience

Hubert van den Bergh, Georges Wagnières, Alain Woodtli

Cancer, when detected at an early stage, has a very good probability of being eradicated by surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates of cure without the side effects of radical therapy. We report on the r ...

Hindawi Publishing Corporation1999

Clinical photodynamic therapy for superficial cancer in the esophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II

Hubert van den Bergh, Georges Wagnières

Photodynamic therapy (PDT) for cancer in the esophagus and bronchi with red (630 nm) light may occasionally lead to wall perforation and fistula. Therefore, the clin. use of a less penetrating wavelength (514 nm) was investigated for the curative treatment ...

1998